Psoriasis is driven by a self-reinforcing loop between the immune system and the skin, where genetic susceptibility sets the stage and environmental triggers pull the curtain. At the center of this loop sits the IL-23/IL-17 signaling axis, a cytokine cascade that pushes keratinocytes into overdrive, producing the thickened, inflamed plaques that define the disease. But calling psoriasis a “skin disease” sells it short. The inflammatory machinery spills beyond the skin, connecting to cardiovascular risk, joint destruction, and metabolic dysfunction in ways researchers are still mapping out.
The Core Immune Loop
The hallmark of psoriasis at the cellular level is a feed-forward cycle. Dendritic cells in the skin release IL-23, which activates a subset of T cells that, in turn, produce IL-17 cytokines. The IL-17 family members, particularly IL-17A, IL-17C, IL-17E, and IL-17F, act on keratinocytes, endothelial cells, and other immune cells to stimulate the rapid skin-cell turnover and chronic inflammation seen in plaque psoriasis.1Europe PMC. The Role of IL-17 Cytokines in Psoriasis Keratinocytes are not passive bystanders here. When hit with IL-17A, they ramp up production of antimicrobial proteins and additional inflammatory signals, which recruit more immune cells into the skin and keep the cycle spinning.2Immunity. The Antimicrobial Protein REG3A Regulates Keratinocyte Proliferation and Differentiation after Skin Injury
The result is a skin environment where the normal turnover of surface cells, which usually takes about a month, compresses to just a few days. Immature cells pile up on the surface before they can flatten and shed properly, forming the silvery, scaly plaques. Meanwhile, dilated blood vessels beneath the plaques give lesions their red or dark appearance, and infiltrating immune cells keep the tissue chronically inflamed.
Upstream of IL-17, tumor necrosis factor-alpha (TNF-α) and IL-6 also contribute. TNF-α promotes the proliferation of T cells and keratinocytes within psoriatic lesions, and its serum levels tend to track with disease severity. IL-6 similarly activates T cells and drives keratinocyte growth. Together with IL-1β, these cytokines form a trio whose levels rise during active disease and fall with successful treatment.3PubMed Central. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis This layered cytokine network helps explain why blocking just one molecule, whether TNF-α, IL-17, or IL-23, can produce dramatic clinical improvement: you’re disrupting a critical node in the feedback loop.
What Starts the Loop in the First Place
A persistent puzzle in psoriasis research has been identifying what the immune system is actually reacting to. One answer came from the discovery that about two-thirds of patients with moderate-to-severe plaque psoriasis carry T cells that specifically recognize LL37, an antimicrobial peptide that the skin naturally produces to fight infection. In psoriasis, LL37 is overexpressed, and the immune system treats it as a target. Both CD4 and CD8 T cells that recognize LL37 have been found infiltrating psoriatic skin, and the number of these cells circulating in the blood correlates with disease activity.4PubMed. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
This is significant because it reframes psoriasis as partly autoimmune, not just autoinflammatory. The immune system is not simply overreacting to nothing; it has identified a self-molecule as a threat. LL37-specific T cells produce interferon-gamma and Th17 cytokines, feeding directly into the IL-17 cascade described above. The discovery also helps explain why psoriasis tends to recur in the same locations: the immune memory at those sites keeps recognizing the same autoantigen.
Genetic Susceptibility and HLA-Cw6
Psoriasis has a strong hereditary component. If one identical twin has it, the other has a roughly 70% chance of developing it too. The single strongest genetic risk factor identified so far is an immune-system gene called HLA-Cw6 (also written HLA-C*06:02). This gene variant sits in a region of chromosome 6 known as PSORS1, the first psoriasis susceptibility locus ever mapped. In a large genetic analysis, carrying the HLA-Cw*0602 allele was associated with about a fourfold increase in psoriasis risk compared to not carrying it.5PLoS Genetics. Multiple Loci within the Major Histocompatibility Complex Confer Risk of Psoriasis
Pinpointing HLA-Cw6 as the culprit gene required untangling it from neighboring genes that travel together on the same stretch of DNA. Researchers accomplished this by studying people who had rare recombinations in that chromosomal region: individuals who inherited HLA-Cw6 without a nearby gene variant called CDSN*TTC still had elevated psoriasis risk, whereas those who inherited CDSN*TTC without HLA-Cw6 did not.6PubMed Central. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene That natural experiment fingered HLA-C as the true risk gene. HLA-C encodes a molecule that presents peptide fragments to immune cells, so carrying the Cw6 version likely alters which self-peptides are flagged for immune attention, potentially including fragments of LL37.
A second HLA-C allele, HLA-Cw*1203, also showed a modest association with psoriasis risk even in people who do not carry Cw6, suggesting the HLA-C gene’s influence is broader than just one variant.5PLoS Genetics. Multiple Loci within the Major Histocompatibility Complex Confer Risk of Psoriasis
Beyond HLA-C
HLA-C dominates the genetic landscape, but psoriasis is polygenic. Genome-wide association studies have turned up more than 80 susceptibility loci spread across the genome, many of which affect immune signaling, skin barrier integrity, or both. Among the non-HLA genes, mutations in IL36RN (encoding the IL-36 receptor antagonist) and CARD14 (a signaling scaffold protein in keratinocytes) have been linked to pustular forms of psoriasis, where the inflammatory response is especially intense.7PubMed Central. Case report: Infantile generalized pustular psoriasis with IL36RN and CARD14 gene mutations IL-36 is part of the IL-1 cytokine superfamily, and when its natural brake is defective, the inflammatory signal goes unchecked.
This genetic complexity means there is no single “psoriasis gene.” Instead, many small-effect variants combine to tilt the immune system toward inflammatory overreaction. Environmental triggers then determine when and whether that tilt becomes clinical disease.
Epigenetics and the Space Between Genes and Environment
If genetics loads the gun, epigenetics may help pull the trigger. Epigenetic changes, such as DNA methylation, histone modification, and regulation by small RNA molecules called microRNAs, can switch genes on or off without altering the underlying DNA sequence. In psoriasis, researchers have found altered methylation patterns and abnormal microRNA expression in affected skin, suggesting that environmental exposures can reprogram gene activity in ways that sustain the disease.8PubMed Central. The Role of Epigenetic Factors in Psoriasis
Epigenetic modifications may also help explain why psoriasis risk alleles do not guarantee disease. Two people can carry the same HLA-Cw6 variant, but differences in how the surrounding chromatin is packaged could determine whether that allele is actively expressed in the skin’s immune cells. Some researchers have proposed that epigenetics is the missing link between inherited susceptibility and clinical flares, since these modifications can be influenced by smoking, diet, infections, and psychological stress.9PubMed. Epigenetics in the pathogenesis and pathophysiology of psoriasis vulgaris
Physical Triggers and the Koebner Phenomenon
People with psoriasis often notice new plaques appearing at sites of skin injury: a scrape, a surgical wound, even a sunburn. This is the Koebner phenomenon, and it happens because keratinocytes can sense mechanical stress and translate it into inflammatory signaling. When skin is physically disrupted, stressed keratinocytes activate mechano-induced pathways that recruit immune cells to the site.10PubMed. Characteristics and pathogenesis of Koebner phenomenon The same mechanism explains why psoriasis lesions cluster on the extensor sides of elbows and knees, areas of the body subject to repeated friction and stretching.
For people living with psoriasis, the practical implication is that protecting the skin from unnecessary trauma matters. Tattoos, aggressive exfoliation, and even tight clothing at friction points can provoke new lesions. Koebner responses vary between patients and even between flares in the same patient, so avoiding injury does not guarantee clear skin, but it reduces one known trigger.
Infections as Triggers
Strep throat is probably the most well-documented infectious trigger for psoriasis. Guttate psoriasis, a form that appears as small, drop-shaped lesions scattered across the trunk and limbs, frequently follows a streptococcal throat infection, especially in children and young adults. The connection involves superantigens, bacterial proteins capable of activating large numbers of T cells simultaneously. Streptococcal isolates from patients with guttate psoriasis secrete a superantigen called streptococcal pyrogenic exotoxin C, which drives a broad T-cell expansion in the skin that bears the hallmarks of superantigen stimulation rather than a targeted response to a single pathogen fragment.11JCI Insight. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis
This wave of T-cell activation can prime the IL-17 pathway and, in someone with the right genetic background, tip the immune balance toward sustained skin inflammation. Guttate psoriasis sometimes resolves on its own, but in a subset of patients, it transitions into chronic plaque psoriasis, suggesting that the initial infection establishes an immune memory that persists long after the bacteria are cleared.
Stress, Nerves, and the Brain-Skin Connection
Patients frequently report that psychological stress triggers or worsens their psoriasis, and the research backs this up. The connection runs through both the nervous system and the hormonal stress response. Sensory nerve fibers in psoriatic skin undergo structural remodeling, increasing their release of neuropeptides like substance P, calcitonin gene-related peptide (CGRP), and vasoactive intestinal peptide. These neuropeptides activate dendritic cells, promote T-cell proliferation, and stimulate keratinocytes to produce cytokines, sustaining what researchers call a neurogenic inflammatory loop.12PubMed. Neurogenic Inflammation and Immune Dysregulation in Psoriasis: Mechanistic Pathways and Emerging Interventions
On top of that, psychological stress dysregulates the hypothalamic-pituitary-adrenal (HPA) axis, the body’s central stress-response system. The result is altered cortisol signaling, which normally keeps inflammation in check. When cortisol regulation goes sideways, immune cells in the skin receive less restraint, and the inflammatory cascade intensifies.13PubMed Central. Effects of Neuropeptides on Dendritic Cells in the Pathogenesis of Psoriasis This two-pronged mechanism, local nerve-driven inflammation plus systemic hormonal disruption, creates a particularly stubborn flare pattern during periods of chronic stress.
Obesity and Metabolic Crosstalk
The relationship between psoriasis and obesity runs deeper than coincidence. Dysfunctional fat tissue in obesity secretes the same pro-inflammatory cytokines that drive psoriasis: TNF-α, IL-1β, and IL-6. These shared mediators create a feedback loop where excess body fat amplifies skin inflammation, and chronic skin inflammation may in turn promote the accumulation of visceral fat.3PubMed Central. New insights into different adipokines in linking the pathophysiology of obesity and psoriasis Longitudinal imaging studies have shown that the chronic inflammation of psoriasis promotes visceral fat deposition over time, which in turn worsens metabolic health and may accelerate atherosclerosis.14PubMed Central. Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over time
Weight loss, when achievable, can meaningfully improve psoriasis severity. Several clinical trials have demonstrated that patients who lose weight show reduced disease activity and better responses to treatment. The mechanism likely involves lowering the baseline level of circulating inflammatory cytokines, which makes the immune system’s contribution to skin disease less overwhelming.
Medications That Can Provoke or Worsen Psoriasis
Certain drugs are known to trigger new psoriasis or worsen existing disease. Beta-blockers are among the most frequently cited culprits. They lower intracellular levels of cyclic AMP (cAMP), which in turn raises calcium concentrations inside keratinocytes and immune cells. Higher intracellular calcium accelerates keratinocyte proliferation and disrupts the normal function of immune cells in the skin, creating conditions favorable for plaque formation.15PubMed Central. Mechanisms of Beta-Blocker Induced Psoriasis, and Psoriasis De Novo at the Cellular Level
Other commonly implicated drug classes include lithium, antimalarials (especially chloroquine and hydroxychloroquine), and certain interferons used to treat hepatitis or cancer.16PubMed Central. Drug-provoked psoriasis: is it drug induced or drug aggravated? The distinction between drug-induced psoriasis (new onset in someone without the disease) and drug-aggravated psoriasis (worsening of pre-existing disease) matters clinically, because drug-induced cases sometimes resolve after stopping the medication while drug-aggravated cases may not. If you have psoriasis and are prescribed one of these medications, the decision involves weighing cardiac or psychiatric benefit against skin impact, ideally with both prescribing physician and dermatologist in the conversation.
Cardiovascular Risk and Shared Inflammatory Pathways
Psoriasis affects roughly 2 to 3 percent of the U.S. population, and patients with the condition are up to 50% more likely to develop cardiovascular disease compared to the general population, with risk scaling alongside skin severity.17PubMed Central. Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week The reason is not simply that psoriasis patients happen to smoke more or exercise less, though those factors can compound the problem. The inflammatory molecules at the heart of psoriasis, IL-17, IL-6, and TNF-α, also promote vascular inflammation, endothelial dysfunction, and the plaque buildup that leads to heart attacks and strokes.18International Journal of Research in Dermatology. Psoriasis and increased cardiovascular risk: cutaneous inflammation as a systemic marker-the role of IL-17 and endothelial dysfunction
This insight has changed how dermatologists think about psoriasis management. Treating skin inflammation is not just cosmetic. Aggressive control of the systemic inflammatory burden may protect the heart and blood vessels over the long term. Some early data suggest that biologic therapies, by suppressing the cytokine cascade, could reduce cardiovascular events, though large definitive trials are still needed.
Psoriatic Arthritis and the Enthesis
Up to about 30% of people with psoriasis develop psoriatic arthritis, an inflammatory joint condition that can cause pain, stiffness, and permanent joint damage. The enthesis, the connective tissue where tendons and ligaments attach to bone, appears to be a key site where the disease initiates. Mechanical stress at these attachment points increases local expression of immune-cell-attracting chemicals, drawing innate immune cells into the area. IL-17 acts as a major inflammatory mediator in the enthesis, triggering neutrophil invasion and the release of further inflammatory signals including prostaglandin E2.19PubMed Central. Immune response and cytokine pathways in psoriatic arthritis: A systematic review
The shared role of IL-17 in both skin and joint disease helps explain why biologic drugs targeting this cytokine can address both manifestations simultaneously. It also explains why psoriatic arthritis tends to affect weight-bearing joints and the fingers and toes, where mechanical loading on the entheses is greatest.
Why Psoriasis Keeps Coming Back
Even when psoriatic plaques clear completely, whether from treatment or spontaneous remission, they tend to recur in the same locations. This pattern points to a form of inflammatory memory embedded in the skin. Tissue-resident memory T cells persist at previously affected sites, along with Langerhans cells and dermal dendritic cells that remain primed for reactivation. Emerging research using single-cell analysis has also implicated keratinocytes and fibroblasts themselves, non-immune cells that appear to retain an epigenetic imprint of prior inflammation.20PubMed. Inflammatory memory in psoriasis: From remission to recurrence
This inflammatory memory is a major frontier in psoriasis research because it represents the difference between suppression and cure. Current biologic therapies do an excellent job of quieting the inflammatory cascade while you take them, but they do not erase the memory. If treatment stops, the resident immune cells can reboot the cycle relatively quickly. Strategies aimed at resetting this tissue-level memory, potentially through targeted depletion of resident memory T cells, are under active investigation but remain experimental.
Biologics That Target the Pathway
Understanding the IL-23/IL-17 axis transformed psoriasis treatment. The FDA has approved multiple biologic therapies that interrupt this signaling cascade at different points. Secukinumab, ixekizumab, and brodalumab block IL-17 or its receptor, while guselkumab and tildrakizumab block IL-23.21The Journal of Immunology. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis The two classes have distinct clinical profiles: IL-17 inhibitors tend to work fast and produce near-complete skin clearance in many patients, while IL-23 inhibitors offer strong long-term durability with dosing intervals that can stretch to every two or three months.22Biomolecules & Therapeutics. Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis
Older biologics targeting TNF-α (etanercept, adalimumab, infliximab) remain in use, particularly for patients who also have psoriatic arthritis or inflammatory bowel disease, where TNF plays a more central role. But for skin-predominant disease, the newer IL-17 and IL-23 inhibitors generally produce higher rates of near-complete clearance. The choice between them often depends on individual factors: speed of response needed, dosing convenience, insurance coverage, and whether the patient has comorbidities that favor one mechanism over another.
The Gut Microbiome as an Emerging Piece of the Puzzle
A newer line of research explores whether the trillions of microbes in the gut influence psoriasis through immune-system regulation. Patients with psoriasis tend to show altered gut bacterial composition compared to healthy controls, with reduced microbial diversity and shifts in the balance of specific bacterial groups.23PubMed Central. Gut Microbiota in Psoriasis The gut microbiome shapes the development and calibration of immune responses throughout the body, so disruptions could plausibly lower the threshold for autoimmune and autoinflammatory conditions.
The evidence here is still largely observational, and it remains unclear whether gut dysbiosis is a cause, a consequence, or simply a fellow traveler of psoriatic inflammation. A few small interventional studies have explored probiotics and dietary modification, with mixed results. The microbiome is likely one piece of a much larger environmental puzzle, relevant but not yet actionable in the way that, say, biologic therapy is. It is worth watching as the research matures, but premature to treat psoriasis primarily through the gut.